While Geron Corporation (NASDAQ:GERN) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 29% in the last quarter.

Geron is also testing the drug for myelofibrosis (MF), another form of bone marrow cancer, and expects data from the phase 3 IMpactMF trial of imetelstat in relapsed/refractory MF in 2024.

Local students from Clark, Floyd and Harrison counties named to the Dean's List and Chancellor's List for the Fall Semester.

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo. The US regulator has cleared Rytelo ...

After hours: January 24 at 7:36:18 p.m. EST ...

Things are heating up in Phoenix. Thomas averaged 10.6 points, 8.4 rebounds and 7.9 assists last season, while shooting 50.9% from the field. Thomas led the Sun to a playoff berth in 2024, marking ...

Alyssa Jackson joined the KSHB 41 team in April 2023 and knows Missouri well. She is from St. Louis, graduated from the University of Missouri School of Journalism and reported, produced and ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.